Legal & General Group’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-19,147
| Closed | -$289K | – | 3458 |
|
|
2022
Q3 | $289K | Sell |
19,147
-17,878
| -48% | -$208K | ﹤0.01% | 2485 |
|
|
2022
Q2 | $278K | Buy |
37,025
+20,231
| +120% | +$143K | ﹤0.01% | 2522 |
|
|
2022
Q1 | $153K | Buy |
16,794
+149
| +0.9% | +$1.15K | ﹤0.01% | 2760 |
|
|
2021
Q4 | $117K | Hold |
16,645
| – | – | ﹤0.01% | 2877 |
|
|
2021
Q3 | $190K | Buy |
16,645
+8,790
| +112% | +$128K | ﹤0.01% | 2710 |
|
|
2021
Q2 | $126K | Buy |
7,855
+404
| +5% | +$6.93K | ﹤0.01% | 2668 |
|
|
2021
Q1 | $133K | Sell |
7,451
-11,296
| -60% | -$195K | ﹤0.01% | 2542 |
|
|
2020
Q4 | $253K | Hold |
18,747
| – | – | ﹤0.01% | 2373 |
|
|
2020
Q3 | $220K | Sell |
18,747
-1,797
| -9% | -$21.9K | ﹤0.01% | 2342 |
|
|
2020
Q2 | $303K | Sell |
20,544
-541
| -3% | -$8K | ﹤0.01% | 2276 |
|
|
2020
Q1 | $285K | Sell |
21,085
-1,959
| -9% | -$37.2K | ﹤0.01% | 2205 |
|
|
2019
Q4 | $557K | Buy |
23,044
+1,714
| +8% | +$35.5K | ﹤0.01% | 2202 |
|
|
2019
Q3 | $410K | Buy |
21,330
+1,628
| +8% | +$37.3K | ﹤0.01% | 2197 |
|
|
2019
Q2 | $582K | Buy |
19,702
+1,963
| +11% | +$75.6K | ﹤0.01% | 2113 |
|
|
2019
Q1 | $842K | Buy |
17,739
+147
| +0.8% | +$6.47K | ﹤0.01% | 2016 |
|
|
2018
Q4 | $635K | Buy |
17,592
+5,828
| +50% | +$273K | ﹤0.01% | 2052 |
|
|
2018
Q3 | $724K | Sell |
11,764
-192
| -2% | -$12.3K | ﹤0.01% | 2038 |
|
|
2018
Q2 | $808K | Sell |
11,956
-492
| -4% | -$27.5K | ﹤0.01% | 1984 |
|
|
2018
Q1 | $675K | Sell |
12,448
-2,064
| -14% | -$115K | ﹤0.01% | 2037 |
|
|
2017
Q4 | $872K | Buy |
14,512
+1,267
| +10% | +$76.8K | ﹤0.01% | 1938 |
|
|
2017
Q3 | $644K | Buy |
13,245
+5,711
| +76% | +$312K | ﹤0.01% | 2022 |
|
|
2017
Q2 | $396K | Buy |
7,534
+519
| +7% | +$24.2K | ﹤0.01% | 2102 |
|
|
2017
Q1 | $319K | Sell |
7,015
-206
| -3% | -$9.19K | ﹤0.01% | 2134 |
|
|
2016
Q4 | $273K | Buy |
7,221
+2,712
| +60% | +$103K | ﹤0.01% | 2137 |
|
|
2016
Q3 | $171K | Buy |
4,509
+673
| +18% | +$14.8K | ﹤0.01% | 2076 |
|
|
2016
Q2 | $68K | Hold |
3,836
| – | – | ﹤0.01% | 2316 |
|
|
2016
Q1 | $47K | Buy |
3,836
+461
| +14% | +$7.29K | ﹤0.01% | 2446 |
|
|
2015
Q4 | $81K | Hold |
3,375
| – | – | ﹤0.01% | 2207 |
|
|
2015
Q3 | $59K | Buy |
3,375
+1,176
| +53% | +$21.3K | ﹤0.01% | 2363 |
|
|
2015
Q2 | $38K | Hold |
2,199
| – | – | ﹤0.01% | 2637 |
|
|
2015
Q1 | $69K | Hold |
2,199
| – | – | ﹤0.01% | 2300 |
|
|
2014
Q4 | $65K | Hold |
2,199
| – | – | ﹤0.01% | 2280 |
|
|
2014
Q3 | $45K | Buy |
+2,199
| New | +$43.4K | ﹤0.01% | 2449 |
|
Legal & General Group's AERI Position: Q4 2022 in Review
Legal & General Group sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 19,147 shares — an estimated $289K sold.
Legal & General Group first reported a position in AERI in Q3 2014 and held it in 33 quarters. The position peaked at $872K in Q4 2017. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Legal & General Group reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Legal & General Group sold 19,147 Aerie Pharmaceuticals shares in Q4 2022, an estimated $289K.
- Legal & General Group first reported a position in Aerie Pharmaceuticals in Q3 2014 and held it in 33 quarters.
- Legal & General Group's Aerie Pharmaceuticals position peaked at $872K in Q4 2017.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Legal & General Group's 13F filing for Q4 2022, filed 14 Feb 2023.